Bennu acquires rights from UCSD to develop cysteamine

Mar 20, 2008 (Datamonitor via COMTEX) -- RPTP | news | PowerRating | PR Charts -- Bennu Pharmaceuticals, a clinical development subsidiary of Raptor Pharmaceuticals, has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego, around the use of cysteamine, and delayed release cysteamine for the treatment of non-alcoholic steatohepatitis.

In collaboration with doctors from University of California, San Diego (UCSD) School of Medicine, Bennu plans to initiate a Phase IIa clinical study of delayed release cysteamine (DR Cysteamine) in non-alcoholic steatohepatitis (NASH) patients in 2008.

Ted Daley, president of Bennu, said: "We are delighted to extend our relationship with UCSD. Additional rights to cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index